

Annacarmen Petrizzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8726399/publications.pdf>

Version: 2024-02-01

29
papers

914
citations

516215

16
h-index

525886

27
g-index

30
all docs

30
docs citations

30
times ranked

1585
citing authors

#	ARTICLE	IF	CITATIONS
1	Translating Tumor Antigens into Cancer Vaccines. <i>Vaccine Journal</i> , 2011, 18, 23-34.	3.2	183
2	Antigen-specific vaccines for cancer treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3332-3346.	1.4	124
3	Challenges in cancer vaccine development for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 897-903.	1.8	87
4	Immunotherapy in hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2019, 18, 291-297.	0.6	66
5	Combinatorial immunotherapy strategies for hepatocellular carcinoma. <i>Current Opinion in Immunology</i> , 2016, 39, 103-113.	2.4	52
6	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. <i>Cancer Letters</i> , 2020, 473, 25-32.	3.2	40
7	High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. <i>Cancers</i> , 2019, 11, 1824.	1.7	36
8	Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?. <i>Immunotherapy</i> , 2011, 3, 1203-1222.	1.0	34
9	Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1305-1314.	2.0	31
10	Potentiating cancer vaccine efficacy in liver cancer. <i>Oncolimmunology</i> , 2018, 7, e1488564.	2.1	26
11	Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. <i>Journal of Translational Medicine</i> , 2018, 16, 286.	1.8	24
12	Immunological effects of a novel RNA-based adjuvant in liver cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 103-112.	2.0	23
13	Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. <i>Scientific Reports</i> , 2016, 6, 29258.	1.6	22
14	Cellular prognostic markers in hepatocellular carcinoma. <i>Future Oncology</i> , 2015, 11, 1591-1598.	1.1	20
15	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. <i>Oncotarget</i> , 2018, 9, 3576-3589.	0.8	19
16	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. <i>Journal of Translational Medicine</i> , 2016, 14, 58.	1.8	18
17	Human Endogenous Retrovirus Reactivation: Implications for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1999.	1.7	16
18	Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. <i>Journal of Translational Medicine</i> , 2010, 8, 18.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles. <i>Journal of Translational Medicine</i> , 2013, 11, 127.	1.8	12
20	Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. , 2016, 4, 71.		12
21	Innate immunity and hepatitis C virus infection: a microarray's view. <i>Infectious Agents and Cancer</i> , 2012, 7, 7.	1.2	11
22	Systems Biology Approach for Cancer Vaccine Development and Evaluation. <i>Vaccines</i> , 2015, 3, 544-555.	2.1	10
23	Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. <i>Infectious Agents and Cancer</i> , 2008, 3, 13.	1.2	9
24	Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. <i>Journal of Translational Medicine</i> , 2014, 12, 11.	1.8	8
25	Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy. <i>Journal of Translational Medicine</i> , 2021, 19, 89.	1.8	8
26	Immunogenomics approaches for vaccine evaluation. <i>Journal of Immunotoxicology</i> , 2012, 9, 236-240.	0.9	5
27	Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a Candidate Idiotype Vaccine for HCV-Related Lymphoproliferative Disorders. <i>PLoS ONE</i> , 2012, 7, e44870.	1.1	4
28	Systems vaccinology for cancer vaccine development. <i>Expert Review of Vaccines</i> , 2014, 13, 711-719.	2.0	2
29	Corrigendum to: "Challenges in cancer vaccine development for hepatocellular carcinoma" [<i>Hepatology</i> 2013;59:897-903]. <i>Journal of Hepatology</i> , 2014, 60, 237.	1.8	0